Circassia Pharma PLC (LON:CIR) has undertaken a major overhaul of its board and senior management.
Steve Harris is stepping down as chief executive of the respiratory drug specialist after thirteen years, with Ian Johnson appointed executive chairman as his replacement.
Johnson is best known from his time as executive chairman of Bioquell and is currently the non-executive chair of Redcentric and on the board at Ergomed.
Garry Watts is also joining the drug group as a senior independent director following existing chairman Francesco Granata’s decision to retire.
In August, Circassia appointed Johnathan Emms to the new role of chief operating officer.
Steve Harris said: "After many years leading Circassia, the company has undergone major transformation and I am delighted we have attracted such a high calibre leader as Ian to take the business to the next level, alongside our recently appointed highly experienced Chief Operating Officer, Jonathan Emms.
“With our preparations well advanced for the forthcoming US launch of Duaklir, the ongoing establishment of our new Chinese sales team in the marketplace and our growing commercial presence in Europe, we look forward to Jonathan leading our commercial strategy.
Circassia also repeated earlier guidance that full-year 2019 revenues will be between £60 - £65mln (2018: £48.3mln) with cash outflows the second half to drop 'drastically'.